Virtual Library
Start Your Search
Ibaraki Pathologist Association
Author of
-
+
P1.09 - Pathology (Not CME Accredited Session) (ID 941)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.09-05 - Why Does PD-L1 (22C3) Expression Rate Show Difference Among Regional Hospitals? (ID 12123)
16:45 - 18:00 | Author(s): Ibaraki Pathologist Association
- Abstract
Background
The immune checkpoints inhibitors, such as anti-programmed cell death 1 (PD-1) receptor antibodies and anti-PD-L1 (its major ligand against PD-1) were applied for several advanced cancer. On 2017, Pembrolizumab was approved for non-small cell lung cancer (NSCLC) as 2nd immune checkpoint inhibitor in Japan. At same time, immuneohistochemical examination by anti-PD-L1 antibody (22c3) was approved as companion diagnostic staining for Pembrorizumab treatment. However, PD-L1 expression rate shows quite difference among hospitals in routine clinical examination. The purpose of this study is probed the reason of the difference in each hospital.
a9ded1e5ce5d75814730bb4caaf49419 Method
The questionnaire about PD-L1 staining was sent via e-mail to 14 Hospitals in Ibaraki prefecture, Japan. The questionnaire included PD-L1 expression in each histology (adenocarcinoma (AD), squamous cell carcinoma (SQ), and other NSCLC, and fixation condition.
4c3880bb027f159e801041b1021e88e8 Result
Eleven hospitals (A to K) answered with the questionnaire. Total staining cases were 651: ADs were 384, SQs were 185 and the other NSCLCs were 79. The rates of PD-L1 No expression showed 18% to 71% among each hospitals. (figure 1 and 2)
8eea62084ca7e541d918e823422bd82e Conclusion
The result of TPS is quite different from clinical study. The reason is thought to be caused of the histological configuration was appreciably difference among regional hospitals.
6f8b794f3246b0c1e1780bb4d4d5dc53